Topics

NICE Rejects Treatments for Head and Neck Cancer and AML

17:58 EST 15 Jan 2020 | OncLive

The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.

Original Article: NICE Rejects Treatments for Head and Neck Cancer and AML

NEXT ARTICLE

More From BioPortfolio on "NICE Rejects Treatments for Head and Neck Cancer and AML"

Quick Search

Relevant Topic

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...